Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 02:15 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Effects of Dronedarone on Cardiac Geometry and Function in Patients With Atrial Fibrillation and Left Atrial Enlargement
NCT01198873 · Sanofi · PHASE4 · terminated · last registry update 2013-02-12 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
No reason was published
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | The registry record gives no reason | – | Registry record, Sanofi |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CACNA1C within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2013-12-20Phase 3 first posted: Prof Brian Lawlor, Nilvadipine + Placebo (NCT02017340)
- 2013-12-16Results posted on the registry: Antonios Likourezos, Metoprolol + Diltiazem (NCT01914926)
- 2013-11-14Phase 3 first posted: Chong Kun Dang Pharmaceutical, TELMINUVO Tab. (80/2.5mg) + TELMINUVO Tab. (80/5mg) (NCT01983735)
- 2013-10-28Results posted on the registry: The George Institute, a drug against CACNA1C (NCT00716079)
- 2013-05-20Phase 3 first posted: Daiichi Sankyo Co., Ltd., DU-176b 15mg + DU-176b 30mg (NCT01857622)
- 2013-04-11Also stopped (terminated): Sanofi, Dronedarone + Placebo (for Dronedarone) (NCT01135017)
- 2013-04-04Results posted on the registry: Mayo Clinic, FDA approved rate and rhythm control drugs (NCT00589303)
- 2013-04-04Also stopped (terminated): Mayo Clinic, FDA approved rate and rhythm control drugs (NCT00589303)
- 2013-04-01Results posted on the registry: Sanofi, Dronedarone + Placebo (for Dronedarone) (NCT01135017)
- 2013-03-08Results posted on the registry: Duke University, Nicardipine + 0.9% saline (NCT00508118)
- 2013-01-18Phase 3 first posted: University Hospital, Strasbourg, France, Placebo + Diltiazem (NCT01771978)
- 2013-01-04Results posted on the registry: Mayo Clinic, Rate Control + Rate Control (NCT00578617)
- 2012-11-16Also stopped (withdrawn): Bayer, Adalat XL + Tiazac XC (NCT00713011)
- 2012-10-26Results posted on the registry: Sanofi, Dronedarone + Placebo (for Dronedarone) (NCT01151137)
- 2012-10-26Also stopped (terminated): Sanofi, Dronedarone + Placebo (for Dronedarone) (NCT01151137)
- 2012-09-21Phase 3 first posted: Ventrus Biosciences, Inc, VEN 307 + Placebo (NCT01690221)
- 2012-08-14Results posted on the registry: Boehringer Ingelheim, Dabigatran etexilate plus dronedarone + Dabigatran etexilate (NCT01306162)
- 2012-07-31Also stopped (withdrawn): Gilead Sciences, Ranolazine (NCT01334203)
- 2012-07-06Phase 3 first posted: Chong Kun Dang Pharmaceutical, CKD-828 2.5/40mg + CKD-828 5/40mg (NCT01634295)
- 2012-04-12Results posted on the registry: Kowa Research Institute, Inc., Pitavastatin (NK-104) + Diltiazem (Cardizem LA) 240 mg QD (NCT01422382)
- 2012-03-16Also stopped (withdrawn): Facet Biotech, Cardene® I.V. (NCT00528827)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision